Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug

Marzeptacog alfa (activated) (MarzAA) is an activated recombinant human FVII (rFVIIa) variant developed as subcutaneous (s.c.) administration for the treatment or prevention of bleeding episodes in patients with hemophilia A (HA) or hemophilia B (HB) with inhibitors and other rare bleeding disorders...

Descripción completa

Detalles Bibliográficos
Autores principales: Faraj, Alan, Knudsen, Tom, Desai, Shraddha, Neuman, Linda, Blouse, Grant E., Simonsson, Ulrika S. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755924/
https://www.ncbi.nlm.nih.gov/pubmed/36191169
http://dx.doi.org/10.1002/psp4.12872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755924/
https://www.ncbi.nlm.nih.gov/pubmed/36191169
http://dx.doi.org/10.1002/psp4.12872

Ejemplares similares